



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoryve (roflumilast) cream and foam Page: 1 of 4

Effective Date: 11/13/2024 Last Review Date: 9/19/2024

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Zoryve cream and foam under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Zoryve Cream

Plaque Psoriasis

Zoryve cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

Atopic Dermatitis

Zoryve cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

Zoryve Foam

Zoryve foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

Applicable Drug List:

Zoryve (roflumilast) 0.3% cream
Zoryve (roflumilast) 0.15% cream
Zoryve (foflumilast) 0.3% foam

Policy/Guideline:

Criteria for Initial Approval:

Atopic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the topical treatment of mild to moderate atopic dermatitis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) CREAM 0.15%
- The patient is 6 years of age or older
- The patient has experienced an inadequate treatment response, intolerance, OR has a contraindication to a topical calcineurin inhibitor OR a medium or higher potency topical corticosteroid
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Plaque Psoriasis



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoryve (roflumilast) cream and foam Page: 2 of 4

Effective Date: 11/13/2024 Last Review Date: 9/19/2024

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

Authorization may be granted when the requested drug is being prescribed for the topical treatment of plaque psoriasis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) cream 0.3%
- The patient is 6 years of age or older
- The patient meets ONE of the following:
 - The patient has experienced an inadequate treatment response, intolerance OR has a contraindication to a topical steroid
 - The requested drug will be used on sensitive skin areas (e.g., face, genitals or skin folds)
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Seborrheic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the topical treatment of seborrheic dermatitis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) foam
- The patient is 9 years of age or older
- The patient meets ONE of the following:
 - The patient is less than 16 years of age
 - The patient has experienced an inadequate treatment response, intolerance OR has a contraindication to a topical ketoconazole (i.e., 2% shampoo, 2% cream, 2% foam, 2% gel) OR a topical ciclopirox (i.e., 0.77% gel, 1% shampoo) product
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Criteria for Continuation of Therapy

Atopic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the topical treatment of mild to moderate atopic dermatitis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) cream 0.15%
- The patient is 6 years of age or older
- The patient has achieved or maintained a positive clinical response as evidenced by improvement [(e.g., improvement in or resolution of any of the following signs and symptoms: erythema (redness), edema (swelling), xerosis (dry skin), erosions, excoriations (evidence of scratching), oozing and crusting, lichenification (epidermal thickening), OR pruritus (itching)]
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Plaque Psoriasis



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoryve (roflumilast) cream and foam Page: 3 of 4

Effective Date: 11/13/2024 Last Review Date: 9/19/2024

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

Authorization may be granted when the requested drug is being prescribed for the topical treatment of plaque psoriasis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) cream 0.3%
- The patient is 6 years of age or older
- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., clear, or almost clear outcome, patient satisfaction, etc.)
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Seborrheic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the topical treatment of seborrheic dermatitis when ALL of the following criteria are met:

- The request is for Zoryve (roflumilast) foam
- The patient is 9 years of age or older
- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., clear, or almost clear outcome, improvement from baseline, etc.)
- If additional quantities are being requested, then the requested drug is being prescribed to treat a body surface area that requires more than 60 grams per month

Approval Duration and Quantity Restrictions:

Initial Approval: 3 months

Renewal Approval: 12 months

Quantity Level Limit: 60 grams per 30 days; for body surface areas requiring more than 60gm per month: 120gm per 30 days

References:

1. Zoryve Cream [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2024.
2. Zoryve Foam [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December 2023.
3. Ciclopirox gel [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals Inc., USA; January 2017.
4. Ketoconazole cream [package insert]. Warminster, PA: Tasman Pharma Inc.; July 2021.
5. Ketoconazole foam [package insert]. Florham Park, NJ: Xiromed, LLC.; April 2020.
6. Loprox shampoo [package insert]. Bridgewater, NJ: Bausch Health US, LLC; May 2019.
7. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed May 29, 2024.
8. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 06/04/2024).
9. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. 2021; 84(2):432-470.
10. Menter A, Cordero K, Davis D, et al. Guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol*. 2020;82(1):161-201.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Zoryve (roflumilast) cream and foam Page: 4 of 4

Effective Date: 11/13/2024 Last Review Date: 9/19/2024

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

11. Eichenfield L, Tom W, Berger T, et al. Guidelines of care for the management of atopic dermatitis Section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-132.
12. U.S. Department of Health & Human Services. Burn Triage and Treatment – Thermal Injuries. Chemical Hazards Emergency Medical Management. February 12, 2024. Available at: <https://chemm.hhs.gov/burns.htm>. Accessed June 4, 2024.
13. Dall'Oglio F, Nasca MR, Gerbino C, et al. An Overview of the Diagnosis and Management of Seborrheic Dermatitis. August 6, 2022. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365318/>. Accessed June 5, 2024.
14. Desai S, McCormick E, Friedman A, An Up-to-Date Approach to the Management of Seborrheic Dermatitis. December 2022. 21 (12). Available at: <https://jddonline.com/articles/an-up-to-date-approach-to-the-management-of-seborrheic-dermatitis-S1545961622P1373X/>. Accessed June 5, 2024.
15. Clark GW, Pope SM, Jaboori KA. Diagnosis and Treatment of Seborrheic Dermatitis. *Am Fam Physician*. 2015;91(3):185-190. Available at: <https://www.aafp.org/pubs/afp/issues/2015/0201/p185.html>. Accessed: June 5, 2024.